Study of a new drug for advanced solid tumors with FGFR2 changes
Part of Cancer clinical trials.
This trial tests a new drug (3HP-2827) for people with solid tumors that have spread or can't be removed surgically, and have changes in a gene called FGFR2. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that has spread or cannot be removed by surgery
- Your tumor has a change in the FGFR2 gene
- You are 18 years or older
- You are in good enough health to be up and about (ECOG score 0 or 1)
- You are expected to live at least 12 weeks
- You have not had other cancers in the last 3 years, except for certain types
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, 3HP-2827, for people with advanced solid tumors that have a specific change (alteration) in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing.
This study tests a new drug, KNT-0916, for people with advanced solid tumors that have a specific change in the FGFR2 gene. It may be an option if other treatments haven't worked or aren't available.
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.
Hear when a new Solid Tumors With FGFR2 Alterations, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.